MyD88 adaptor-like D96N is a naturally occurring loss-of-function variant of TIRAP.

Toll-Like Receptors and Cancer Division, German Cancer Research Center, Heidelberg, Germany.
The Journal of Immunology (Impact Factor: 5.52). 02/2010; 184(6):3025-32. DOI: 10.4049/jimmunol.0901156
Source: PubMed

ABSTRACT Signals elicited by TLRs following the detection of microbes are integrated and diversified by a group of four cytoplasmic adaptor molecules featuring an evolutionarily conserved Toll/IL-1R signaling domain. Single nucleotide polymorphisms (SNPs) in TLRs and their adaptor molecules have been shown to influence susceptibility to a range of infectious and other diseases. The adaptor MyD88 adaptor-like (Mal)/Toll/IL-1R-containing adaptor protein is involved in TLR2 and 4 signal transduction by recruiting another adaptor molecule, MyD88, to the plasma membrane. In this study, we used naturally occurring variants of Mal as tools to study the molecular biology of Mal in more detail in cellular model systems and to thereby identify functionally interesting variants whose corresponding nonsynonymous SNPs might be of further epidemiological interest. Of seven reported variants for Mal, we found Mal D96N associated with reduced NF-kappaB signaling and cytokine production after overexpression in HEK293 and Huh-7 cells. The D96N mutation prevented Mal from recruiting its signaling partner MyD88 to the plasma membrane and altered posttranslational modification of Mal. These findings led us to investigate the frequency of heterozygosity for the corresponding SNP rs8177400 in a Caucasian case-control study on the etiology of lymphoma, a disease in which TLRs have been implicated. Although rs8177400 did not modify lymphoma risk in general, its frequency of heterozygosity was accurately determined to 0.97%. Our data add rs8177400 (D96N) to the list of functionally important variants of Mal and warrant further research into its immunological, epidemiological, and diagnostic relevance.

  • [Show abstract] [Hide abstract]
    ABSTRACT: A number of diseases including sepsis, rheumatoid arthritis, diabetes, cardiovascular diseases and hyperinflammatory immune disorders have been associated with Toll like receptor (TLR) 2 and TLR4. Endogenous adaptor protein known as MyD88 adapter-like protein (MAL) bind exclusively to the cytosolic portions of TLR2 and TLR4 to initiate downstream signalling. Brutons tyrosine kinase (BTK) and protein kinase C delta (PKCδ) have been implicated to phosphorylate MAL and activate it to initiate downstream signalling. BTK has been associated with phosphorylation at positions Tyr86 and Tyr106, necessary for the activation of MAL but definite residual target of PKCδ in MAL is still to be explored. To produce a better understanding of the functional domains involved in the formation of MAL-kinase complexes, computer-aided studies were used to characterize the protein-protein interactions (PPIs) of phosphorylated BTK and PKCδ with MAL. Docking and physicochemical studies indicated that BTK was involved in close contact with Tyr86 and Tyr106 of MAL whereas PKCδ may phosphorylate Tyr106 only. Moreover, the electrostatics charge distribution of binding interfaces of BTK and PKCδ were distinct but compatible with respective regions of MAL. Our results implicate that position of Tyr86 is specifically phosphorylated by BTK whereas Tyr106 can be phosphorylated by competitive action of both BTK and PKCδ. Additionally, the residues of MAL which are necessary for interaction with TLR2, TLR4, MyD88 and SOCS-1 also play their roles in maintaining interaction with kinases and can be targeted in future to reduce TLR2 and TLR4 induced pathological responses.
    Computational Biology and Chemistry 04/2014; 51C:22-35. · 1.79 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) have integral roles in host immune and inflammatory response. In TLR signalling, pathogens bind to the receptor, and stimulate the cytoplasmic Toll/interleukin-1 receptor (TIR)-domain to recruit other TIR-domain containing pro-teins. Recruitment of one or more of these TIR-domain proteins, such as MyD88, TIRAP/MAL, TRIF/TICAM-1 and TIRP/TRAM/TICAM-2, to the receptors ultimately results in the downstream activation of transcription factors (e.g. NF-κB), which induce genes necessary for the host defense. 1,2 The principal function of the TIR-domain is presumably in the formation of heteromeric assembly of the receptors and adaptors in the signal transduction process. Crystal struc-tures of TIR-domains from TLR1, TLR2, TLR10 and IL-1RAPL, and solution structure of TIR-domain from MyD88 have been reported. 3-6 More recently, crystal structures of plant TIR-domain from Arabidopsis thaliana and bacterial TIR-domain from Paracoccus denitrificans have been also reported. 7,8 From these studies, several associations mediat-ing the TIR-TIR interaction have been suggested, but the molecular interface involved in the assembly of multiple TIR-domains still remains unclear. TIRAP (TIR-domain containing Adaptor Protein), also known as MAL (MyD88-Adaptor-Like), functions in pair with MyD88 in the downstream of TLR2 and TLR4 signall-ing. 9-11 TIRAP is composed of an N-terminal phosphatidyl-inositol 4,5-bisphosphate (PIP2) -binding domain which is required for membrane localization and a C-terminal TIR-domain which functions primarily to recruit MyD88 to the activated TLR4. 12 TIRAP TIR-domain is conserved among various species (Fig. 1(a)). In humans, carriage of TIRAP Ser180-to-Leu (S180L) polymorphism conferred protection against infectious di-seases possibly by the attenuation of TLR2 signal trans-duction, 13,14 and Asp96-to-Asn (D96N) showed impaired TLR signaling, which resulted from prevention of MyD88 recruitment to the plasma membrane. 15 The analysis of TIRAP structure would further allow us to propose the con-sequences of these variants in regard to TIR-domain inter-actions. In this study, we report the over-expression, crystal-lization, and X-ray crystallographic structural determination of TIR-domain from the human TIRAP. Of note, during the course of our experiment, the same TIRAP TIR-domain Figure 1. Sequence alignment of TIRAP TIR-domain from selected species (a), and the fold of human TIRAP TIR-domain (b). (a) Amino acid sequence comparison of human, chimpanzee, mouse, zebra fish, chicken and frog TIRAP TIR-domain are shown with secondary structural elements on the top according to the human TIRAP TIR-domain structure. Identical residues are boxed, and human Asp96 and Ser180 residues are highlighted. (b) Schematic ribbon diagram of TIRAP (Mol B) with the five-stranded parallel β-sheet (βA–βE) surrounded by five α-helices (αA, αC, αC', αD and αE) are shown. Residues comprising βE and the loops (αA– βB, 111-129 and αC–βD, 167-171) were not visible in the electron density. Residues of Asp96 and Ser180 whose mutants acquire physiological phenotype are shown as stick models.
    Bulletin- Korean Chemical Society 01/2012; 33(9). · 0.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human interleukin-1 receptor-associated kinase 4 (IRAK4) deficiency and myeloid differentiating factor 88 (MyD88) deficiency syndromes are two primary immune-deficiency disorders with innate immune defects. Although new genetic variations of IRAK4 and MyD88 have recently been deposited in the single nucleotide polymorphism (SNP) database, the clinical significance of these variants has not yet been established. Therefore, it is important to establish methods for assessing the association of each gene variation with human diseases. Because cell-based assays, western blotting and an NF-κB reporter gene assay, showed no difference in protein expression and NF-κB activity between R12C and wild-type IRAK4, we examined protein-protein interactions of purified recombinant IRAK4 and MyD88 proteins by analytical gel filtration and NMR titration. We found that the variant of IRAK4, R12C, as well as R20W, located in the death domain of IRAK4 and regarded as a SNP, caused a loss of interaction with MyD88. Our studies suggest that not only the loss of protein expression but also the defect of Myddosome formation could cause IRAK4 and MyD88 deficiency syndromes. Moreover a combination of in vitro functional assays is effective for confirming the pathogenicity of mutants found in IRAK4 and MyD88-deficiency patients.
    Molecular Immunology 12/2013; 58(1):66-76. · 2.65 Impact Factor

Full-text (2 Sources)

Available from
May 22, 2014